CL2007002880A1 - Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d - Google Patents
Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor dInfo
- Publication number
- CL2007002880A1 CL2007002880A1 CL200702880A CL2007002880A CL2007002880A1 CL 2007002880 A1 CL2007002880 A1 CL 2007002880A1 CL 200702880 A CL200702880 A CL 200702880A CL 2007002880 A CL2007002880 A CL 2007002880A CL 2007002880 A1 CL2007002880 A1 CL 2007002880A1
- Authority
- CL
- Chile
- Prior art keywords
- stamp
- acid stamp
- polyol
- excipient
- sugar
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85036206P | 2006-10-06 | 2006-10-06 | |
US85097006P | 2006-10-10 | 2006-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002880A1 true CL2007002880A1 (es) | 2008-05-09 |
Family
ID=39283396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200702880A CL2007002880A1 (es) | 2006-10-06 | 2007-10-05 | Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080112953A1 (es) |
EP (1) | EP2081553B1 (es) |
JP (1) | JP5631591B2 (es) |
AR (1) | AR063150A1 (es) |
AU (1) | AU2007307107B2 (es) |
CA (1) | CA2665567C (es) |
CL (1) | CL2007002880A1 (es) |
ES (1) | ES2827180T3 (es) |
MX (1) | MX2009003635A (es) |
PE (1) | PE20081179A1 (es) |
TW (1) | TW200831129A (es) |
WO (1) | WO2008045373A2 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
CN102301235B (zh) * | 2008-11-28 | 2014-11-19 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
MX2011011772A (es) * | 2009-05-04 | 2012-02-08 | Abbott Biotech Ltd | Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina. |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
EP2473191B1 (en) * | 2009-09-04 | 2017-08-23 | XOMA Technology Ltd. | Antibody coformulations |
WO2011028961A2 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
CN103037899A (zh) | 2010-02-26 | 2013-04-10 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
AU2011257219B2 (en) | 2010-05-28 | 2014-12-04 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
SG186421A1 (en) * | 2010-07-02 | 2013-01-30 | Medimmune Llc | Antibody formulations |
KR101841527B1 (ko) | 2010-11-11 | 2018-03-23 | 애브비 바이오테크놀로지 리미티드 | 개선된 고농도 항-TNFα 항체 액체 제형 |
WO2012111762A1 (ja) * | 2011-02-17 | 2012-08-23 | 協和発酵キリン株式会社 | 抗cd40抗体の高濃度製剤 |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
AR088382A1 (es) * | 2011-10-18 | 2014-05-28 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con xilitol |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
WO2014011672A1 (en) | 2012-07-09 | 2014-01-16 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
BR112015004467A2 (pt) | 2012-09-02 | 2017-03-21 | Abbvie Inc | método para controlar a heterogeneidade de proteínas |
UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
SI2895188T1 (en) | 2012-09-11 | 2018-05-31 | Coherus Biosciences, Inc. | CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE |
EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
CN106061468B (zh) * | 2013-11-29 | 2020-10-02 | 阿雷斯贸易股份有限公司 | 包含TNFR和Fc区的融合蛋白的液体制剂 |
AU2015284236B2 (en) * | 2014-06-30 | 2018-03-08 | Tva (Abc), Llc | Targeted conjugates and particles and formulations thereof |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
AU2015346444A1 (en) | 2014-11-12 | 2017-05-04 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
EP3287139B1 (en) | 2015-04-21 | 2021-08-11 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Nerve growth factor composition and injection powder |
EP3287140B1 (en) | 2015-04-21 | 2021-06-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Nerve growth factor composition and powder injection |
WO2016169455A1 (zh) * | 2015-04-21 | 2016-10-27 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子组合物和注射粉剂 |
US11160871B2 (en) | 2015-10-28 | 2021-11-02 | Tarveda Therapeutics, Inc. | SSTR-targeted conjugates and particles and formulations thereof |
JOP20190189A1 (ar) * | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
GB201703062D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
IL270175B2 (en) * | 2017-05-02 | 2023-09-01 | Merck Sharp & Dohme | Stable formulations of anti-tigit antibodies alone, and in combination with programmed death receptor 1 (pd-1) antibodies, and methods of using them |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CN107898756B (zh) * | 2017-12-22 | 2020-11-20 | 东曜药业有限公司 | 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用 |
KR20210114989A (ko) | 2019-02-18 | 2021-09-24 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
JP2023512446A (ja) * | 2020-01-13 | 2023-03-27 | アプティーボ リサーチ アンド デベロップメント エルエルシー | 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) * | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) * | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US5237054A (en) * | 1987-02-20 | 1993-08-17 | Akzo Pharma | Stabilized aqueous composition containing antibodies |
US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
GB2288732B (en) * | 1994-04-13 | 1998-04-29 | Quadrant Holdings Cambridge | Pharmaceutical compositions |
US5955448A (en) * | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998056418A1 (en) * | 1997-06-13 | 1998-12-17 | Genentech, Inc. | Stabilized antibody formulation |
EP1336410A4 (en) * | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
KR20090125840A (ko) * | 2001-06-13 | 2009-12-07 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (egfr)에 대한 인간 모노클로날 항체 |
DE10133394A1 (de) * | 2001-07-13 | 2003-01-30 | Merck Patent Gmbh | Flüssige Formulierung enthaltend Cetuximab |
JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
CA2466034C (en) * | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
WO2004039826A1 (en) * | 2001-11-14 | 2004-05-13 | Centocor, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
US20040009168A1 (en) * | 2002-04-05 | 2004-01-15 | Elizabet Kaisheva | Multidose antibody formulation |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
MXPA05008409A (es) * | 2003-02-10 | 2005-10-05 | Elan Pharm Inc | Formulacion de inmunoglobulina y metodo para la preparacion de la misma. |
EP1712240B1 (en) * | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
AU2005299716B2 (en) * | 2004-10-22 | 2012-09-06 | Amgen Inc. | Methods for refolding of recombinant antibodies |
JP5670004B2 (ja) * | 2005-03-08 | 2015-02-18 | ファイザー・プロダクツ・インク | 抗ctla−4抗体組成物 |
US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
EA200702143A1 (ru) * | 2005-04-01 | 2008-06-30 | Эмджен Инк. | Способы прогнозирования эффективности и лечения рака по увеличенному числу копий гена |
WO2007145862A2 (en) * | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
-
2007
- 2007-10-05 MX MX2009003635A patent/MX2009003635A/es active IP Right Grant
- 2007-10-05 AU AU2007307107A patent/AU2007307107B2/en active Active
- 2007-10-05 PE PE2007001355A patent/PE20081179A1/es not_active Application Discontinuation
- 2007-10-05 EP EP07839335.2A patent/EP2081553B1/en active Active
- 2007-10-05 JP JP2009531481A patent/JP5631591B2/ja active Active
- 2007-10-05 WO PCT/US2007/021477 patent/WO2008045373A2/en active Application Filing
- 2007-10-05 CA CA2665567A patent/CA2665567C/en active Active
- 2007-10-05 TW TW096137623A patent/TW200831129A/zh unknown
- 2007-10-05 US US11/973,200 patent/US20080112953A1/en not_active Abandoned
- 2007-10-05 ES ES07839335T patent/ES2827180T3/es active Active
- 2007-10-05 CL CL200702880A patent/CL2007002880A1/es unknown
- 2007-10-09 AR ARP070104422A patent/AR063150A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ES2827180T3 (es) | 2021-05-20 |
CA2665567C (en) | 2012-07-03 |
EP2081553B1 (en) | 2020-08-12 |
JP5631591B2 (ja) | 2014-11-26 |
WO2008045373A2 (en) | 2008-04-17 |
TW200831129A (en) | 2008-08-01 |
AU2007307107B2 (en) | 2011-11-03 |
US20080112953A1 (en) | 2008-05-15 |
MX2009003635A (es) | 2009-04-22 |
WO2008045373A3 (en) | 2008-10-16 |
JP2010505852A (ja) | 2010-02-25 |
AU2007307107A1 (en) | 2008-04-17 |
EP2081553A2 (en) | 2009-07-29 |
PE20081179A1 (es) | 2008-09-29 |
CA2665567A1 (en) | 2008-04-17 |
AR063150A1 (es) | 2008-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007002880A1 (es) | Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d | |
CL2007002881A1 (es) | Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo | |
AR114143A2 (es) | Formulaciones de comprimidos revestidos | |
AR106702A2 (es) | Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento | |
BRPI0620229B8 (pt) | formulações farmaceuticas e processos de produção da ditas formulações | |
BRPI0518855A2 (pt) | medicamento para aplicaÇço higiÊnica no ouvido | |
BR112015023391A2 (pt) | formulações compreendendo conjugado droga-anticorpo anti-egfr | |
CL2007002649A1 (es) | Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes. | |
WO2013087716A3 (de) | Fgfr- binder -wirkstoff konjugate und ihre verwendung | |
MY158560A (en) | Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof | |
CL2007001972A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos. | |
GEP20135803B (en) | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives | |
WO2008128049A3 (en) | Tetrahydrobiopterin compositions and methods of measuring | |
BRPI0606115A2 (pt) | processos para a preparação de compostos éteres de pirazol [3,4-d] pirimidina | |
BRPI0822026A2 (pt) | Prepação farmacêutica ou nutracêutica revestida com liberação acentuada de substância ativa no cólon. | |
WO2010031720A3 (en) | Novel antibody formulation | |
FR2932486B1 (fr) | Procede de preparation d'un polyamideimide, polyamideimide et composition comprenant ce polyamideimide. | |
BRPI1009823A2 (pt) | "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit." | |
BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
BRPI0909566A2 (pt) | Linhagem de h. Polymorpha recombinante, processo de elaboração de etanol que compreende o cultivo da linhagem de h. Polymorpha recombinante e ácido nucleico recombinante | |
BRPI0813630A2 (pt) | combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e) | |
IL184774A0 (en) | Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype | |
CL2007003593A1 (es) | Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina. | |
MX2011010634A (es) | Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa. | |
BRPI0914170A8 (pt) | recipiente para produtos medicinais e processo para a produção do mesmo |